Dialog Box

KOREA RARE

Korea Rare, Young Age and Drug Resistant Cancer Study

Lead Institution

National Cancer Centre Korea

Country

South Korea

Program Description

This project is organized to analyse the genomic and proteomic landscape of rare incidence cancers, young aged cancers, and drug resistant cancers from multiple organ sites. We are going to analyse 8 or more different cancers based on biological questions such as resistance to clinical treatments, and molecular mechanisms of early onset. We are planning to provide genomic, transcriptomic, proteomic, and clinical data as well as community resources to foster productive collaboration among cancer researchers.

Program Goals and Expected Outcomes

As this study spans 8 different cancer types, specific questions are developed as below: 

  • Cholangiocarcinoma: Development of precision medicine strategy for cholangiocarcinoma through proteogenomic analysis
  • Cervical cancer: Discovery of precision medical strategy of cervical cancer through systematic proteogenomic analysis
  • Gastric cancer: Identification of treatment response, prognostic factors, and novel therapeutic molecules for gastric cancer by systematic proteogenomic analysis
  • Breast cancer: Characterization and treatment strategies of early-onset breast cancer through proteogenomic analysis in young breast cancer patients under 35 years of age
  • Renal cell carcinoma: Identification of biomarkers and development of therapeutic drugs for intractable kidney cancer based on proteogenomic analysis
  • Medulloblastoma: Proteogenomic study of medulloblastoma for precision medicine strategy
  • Prostate cancer: Investigating the mechanism of acquiring castration resistance through proteogenomic analysis of prostate cancer
  • Head and neck cancer: Enhancement of integrated data on cancer proteogenomics of Korean head and neck cancer
What gaps in existing knowledge will be addressed by the study?

The 8 or more different cancers have clinical unmet needs including resistance and early onset. Although many genomic studies have attempted to address these questions, only a small portion of patients have received benefits with their treatment. To enlarge the scope and layer of cancer-related mechanisms, proteome data will be integrated with other ‘omics data, because the proteins are the major direct effectors of cancer progression.


Program Team

Eun Sook Lee, MD PhD.

Lead Investigator


Name

Role

Institution, location

Jong Bae Park

Director of Proteogenomics Working Group

National Cancer Centre, Korea

Sun-Young Kong

Laboratory medicine, Clinician

National Cancer Centre, Korea

Yoon Jung Chang

Ethics, Clinician

National Cancer Centre, Korea

Dongwan Hong

Genomic data

National Cancer Centre, Korea

Yul Hwangbo

Informatics, Clinician

National Cancer Centre, Korea

Kyong-Ah Yoon

Young age breast cancer

Konkuk University

Seog Yun Park

Pathology, Clinician

National Cancer Centre, Korea

Kui Son Choi

Big data

National Cancer Centre, Korea

Sun Young Rha

ccRCC, Clinician

Yonsei University Health System

Seung-Ki Kim

Paediatric Brain Tumour, Clinician

Seoul National University Hospital

Hong Koo Ha

Prostate cancer, Clinician

Pusan National University Hospital

Young Woo Kim

Gastric cancer, Clinician

National Cancer Centre, Korea

Sang Jae Park

Cholangiocarcinoma, Clinician

National Cancer Centre, Korea

Joo Young Kim

Cervical cancer, Clinician

National Cancer Centre, Korea

Yuh Seog Jung

Head & Neck cancer, Clinician

National Cancer Centre, Korea



Funding Organisations

National Cancer Centre

Goyang city, Korea

ncc.re.kr 


Further Information

Program Website 

Donate